Probiotics (Lactobacillus plantarum HNU082) Supplementation Relieves Ulcerative Colitis by Affecting Intestinal Barrier Functions, Immunity-Related Gene Expression, Gut Microbiota, and Metabolic Pathways in Mice-Reference-Cited by-同舟云学术

Probiotics (Lactobacillus plantarum HNU082) Supplementation Relieves Ulcerative Colitis by Affecting Intestinal Barrier Functions, Immunity-Related Gene Expression, Gut Microbiota, and Metabolic Pathways in Mice

Published:2022-12-21 Issue:6 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Wu Yuqing¹,Jha Rajesh²^ORCID,Li Ao¹,Liu Huanwei¹,Zhang Zeng¹,Zhang Chengcheng³,Zhai Qixiao³,Zhang Jiachao¹⁴^ORCID

Affiliation:

1. Key Laboratory of Food Nutrition and Functional Food of Hainan Province, College of Food Science and Engineering, Hainan University, Haikou, China

2. Department of Human Nutrition, Food and Animal Sciences, College of Tropical Agriculture and Human Resources, University of Hawaii at Manoa, Honolulu, Hawaii, USA

3. School of Food Science and Technology, Jiangnan University, Wuxi, China

4. One Health Institute, Hainan University, Haikou, China

Abstract

Many studies have focused on the therapeutic effect of probiotics on ulcerative colitis (UC), but few studies have paid attention to the mechanism of probiotics, especially the therapeutic effect. This study suggests that Lp082 has a therapeutic effect on colitis in mice.

Funder

Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01651-22

Reference89 articles.

1. The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21 st Century: A Systematic Review of Population-Based Studies

2. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

3. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications